Back to Results
First PageMeta Content
Stallergenes / Allergen immunotherapy / Sublingual immunotherapy / House dust mite / Immunotherapy / Allergy / Allergen / Allergic rhinitis / Rhinitis / Medicine / Allergology / Immunology


Document Date: 2010-07-12 04:39:48

Open Document

File Size: 8,55 MB

Share Result on Facebook

Company

Stallergenes / /

Continent

Europe / /

Country

Germany / Japan / Russia / United States / Brazil / Korea / China / India / /

Event

FDA Phase / /

IndustryTerm

pharmaceutical class / clinical and pharmaceutical expertise / extract sublingual solution / pharmaceutical market / pharmaceutical standards / pharmaceutical products / adherence aid tools / pharmaceutical regulatory requirements / /

MedicalCondition

allergic disease / allergies / severe allergy / disease / severe allergic rhinitis / respiratory allergy diseases / allergy / severe rhinitis / blister / disorder / illness / respiratory allergies / dust mite allergic rhinitis / /

MedicalTreatment

immunotherapy / ALLERGEN IMMUNOTHERAPY / /

Organization

European Medicines Agency / World Allergy Organization / French Allergy Observatory Committee / /

Person

Albert Saporta / /

Position

Chairman / Chairman and CEO Dr louis champion Managing Director Any / Chairman and Chief Executive Officer / /

Product

IR SUBLINGUAL TABLETS / Oralair / Actair® / /

Region

Latin America / /

URL

www.stallergenes.com / /

SocialTag